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Abstract
Introduction: Viruses have always been a major cause of
various disastrous pandemics in mankind’s history. H1N1 be-
came a threat when its original strain was first discovered
back in the swine flu pandemic of 2009. It became highly
catastrophic on a large scale because none of the therapeu-
tic interventions and methodologies that were already present
at the time were effective against the virus.
Methods: A vast amount of literature and research is
available regarding H1N1 influenza from different reputable
sources online. The data was gathered following the con-
trasting and relative situations of 1918 as well as the 2009
pandemic in mind. The overall extracted material provides
comprehensive insights into the ups and downs of H1N1 in-
fluenza from 1918 up to 2009.
Results: H1N1 virus comprises of a huge potential to cause
a pandemic of Influenza type A. The illness caused by the
virus has a varying degree of severity depending on the im-
mune function of the individual being under attack. The virus
exploits droplet-based transmission mode for its spread from
one host to another. The major center of escalation of the
subtypes of virus mostly originates from different avian and
swine species. Most notably subtypes H9N2 and H5N1 of in-
fluenza A, which aren’t easily transmissible among humans.
Furthermore, the droplet-based transmission takes compara-
bly less time to infect a population of thousands if not millions.
This ultimately increases the overall death toll by several folds
by initiating a constant wave of pro-inflammatory cytokine re-
lease among affected hosts.
Conclusion: Since its discovery in 2009, researchers have
developed antiviral drugs and vaccines to fight the virus, most
of which have proven to be very successful in treating the in-
terconnected complications. The present-day strategies are
only efficacious until the current strains of influenza A do not
produce resistance against these drugs. All the therapeutic
techniques and methodologies that have been developed to
confront the virus up until now have been described in this
ample review.
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Introduction
H1N1 is classified as the serotype of the species In-
fluenza A virus, a descendant of the family Orthomyx-
oviridae. H1N1 caused the disastrous swine flu pan-
demic of 2009 that infected 60.8 million people along
with 12,469 deaths and 274,304 hospitalizations just
within a span of a little more than 1.5 years. It is
the same type that caused the infamous influenza pan-
demic of 1918.[1] Other serotypes of Influenza A are
H3N1, H2N3, H1N2, and H3N2. Influenza B and C do
not have serotypes. H5N1, H7N5, and other serotypes
cause Influenza in avian species. Other strains in-
clude H4N6 and H9N2 that infect swine species just
like H1N1. he classification for subtypes of Influenza
A is based on the presence of the glycoprotein Hemag-
glutinin and Neuraminidase. In the reproductive cycle
of the virus, Hemagglutinin performs the clumping ac-
tion on the red blood cells that helps the virus to bind
and infect the cells effortlessly.[2] Locomotion and the
budding action in the infected cell are executed with
the help of Neuraminidase. Neuraminidase belongs to
the category of glycoside hydroxylase enzymes. In gen-
eral, the H1N1 influenza A does not always lead to the
viral infection upon any type of contact to the swine
population but if the contact leads to the infection, it
is termed as zoonotic swine flu.[3] Experimentally, it
has been observed that the virus generally shows its
symptoms in swine within four days and can be easily
transmitted among the individuals of different swine
species, mostly through proper contact.[4–6]
There are different variants of the virus based on the
genotype. For example, the recently discovered strain
in China is G4 H1N1. It is a genotype 4 variant of the
original strain that mainly affects the swine and has
a striking resemblance with the Eurasian avian H1N1
strain. There is little evidence about this variant caus-
ing infection in humans. Severe cases of the infection
of H1N1 mostly happen with pregnant women.[7,8] Fe-
tus related hormonal changes in the body of pregnant
women cause a drop in the function of the immune sys-
tem that paves the way for the virus to cause infec-
tion. This is the reason it is mostly recommended for
pregnant women to get vaccinated to avoid any H1N1-
related complications.[9–12]
Humanity has already faced this kind of H1N1
influenza-related flu pandemic in the past. 1917-18
marks the era of the great disastrous influenza pan-
demic in the pages of history with an approximate
death toll of over 50 million people worldwide. The ad-
vanced medical and therapeutic innovations that we’ve
today weren’t present back then. So, the medical cop-
ping facilities at that time were minute relatively. This
was one of the main reasons why the severity of the
1918 pandemic was enormous as compared to the 2009
influenza pandemic. The mortality rate was far too
high in 1918 but dropped exponentially as time passed
away. However, the original strains of 1918 H1N1 are
still circulating in the population today. The status of
the immune system of the affected hosts was far bet-
ter in 2009 than it was in 1918. Lower immune health
with low cellular immunity as well as a low number
of antiviral cross-reactive antibodies contributed to the
severe pro-inflammatory cytokine storm along with the
spread of H1N1 in the affected hosts of the 1918 pan-
demic. Today, we’re also facing an exponential increase
in the new strain of influenza (like H5N1 and H7N9)
that have evolved since 1918 but the medical advance-
ments are also on a whole different level.[13–15]
2009 Swine Flu: A Brief Overview
During the swine flu pandemic of 2009, cases of pneu-
monia were showing up consistently because of bacte-
rial co-infection along with the virus. A study was per-
formed during the pandemic to quantify the ratio of co-
infection. Although several proportions were reported,
approximately 25% of the total cases were appearing to
have a co-infection. Dealing with this co-infection situ-
ation, was a challenge in 2009 due to the severely com-
promised immune systems of the patients.[16] Later on,
experiments were performed by taking frequent sam-
ples from herds of swine to map out the lineage of
the viruses that were evolving. It was concluded that
swine are a “mixing vessel” of several serotypes that
ultimately helps the virus to become unresponsive to
a lot of newly developed human vaccines. A total of
17 sequenced whole genomes were used in this par-
ticular spatiotemporal distribution study.[17–18] Sim-
ilarly, another study demonstrated in 2011 that the
swine flu virus is antigenically evolved as compared
to the viral strain of the 2009 pandemic. The experi-
ments were performed using ferrets that were immune
to the original strain but were least immune to this new
strain. The concept is the same in the case of humans
who were immune to an old strain, but are vulnera-
ble to this mutated strain.[19–22] Real-time Polymerase
Chain Reaction (PCR) techniques were approved by
WHO (World Health Organization) in 2020 to detect the
presence of the virus. Many new methods, like the use
of biosensors (FET biosensors, PEDOT with galactose,
Surface plasmon resonance, and AuNP immunosen-
sor), have shown high sensitivity to the presence of
DNA (Deoxyribonucleic Acid). The RT-LAMP (Re-
verse Transcription Loop-mediated Isothermal Ampli-
fication) technique that investigates antigen-antibody
related interactions to confirm the presence of the virus
was also utilized.[23] Biosensors are a recent develop-
ment in this field and are very efficient as compared to
other conventional detection methods. Biosensors usu-
ally exploit immune-chromatographic techniques. The
most modern technology uses a bacterial quench-body
that is an immuno-protein adhering to different anti-
bodies labeled with specific fluorophores. The detec-
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Figure 1. A semi-logarithmic chart of laboratory-confirmed A (H1N1) influenza cases by date according to WHO (World Health Organization)
reports.[34]
tion is based on the interaction between antigen and
the quench-body. Examples of quench-body include
anti-HA Fab with ATTO520 (attachment of a Cys-tag at
locus N-terminus of heavy chain in the expression vec-
tor of Fab), anti-BGP Fab, anti-Flag Fab, and anti-His
Fab.[24–27]
All of these detection methods were developed to cope
with the mutated strains of Influenza A that arose
as a result of the phenomenon of divergence. Here,
divergence specifies the outward spread of the mu-
tated strains from the center of origin. Recent studies
have observed the presence of the virus in Australians
with divergent origins from the main human popula-
tion. The diversity in the genotype of different whole-
genome sequenced samples showed that all strains are
somewhat different from each other. The samples that
were taken between 2012 and 2016 revealed that lim-
ited diversity is the main hurdle for risk assessment as
well as for the control procedures. The diversity prob-
lem poses new challenges in the further development
of new treatment methods.[28] Although the 2009 pan-
demic had disastrous effects on the population as the
cases rise with time (Figure 1), it led to an improve-
ment of strategies to manage future infections. In Mex-
ico, the health shocks of the pandemic directed to bet-
ter health control measures that helped health authori-
ties to regulate the causes of diarrhea in young adults.
Furthermore, aftershocks of the pandemic motivated
some people to quit smoking and improve their hy-
giene habits.[29–32] One phylodynamic study also dis-
played that after the pandemic, there was a reduction in
the diversity of the virus globally due to its transition-
ing towards immune-driven selection instead of host-
adaptation mechanisms.[33]
There are some sequence-based studies with strong ev-
idence that 3 out of 5 pandemics of flu have a pos-
sible avian origin. These studies utilized polymerase
derived gene segments that showed that diverse lin-
eages in the swine population of North America are
due to the re-introduction of the original American
avian strains. There was a 70% average match of anti-
genic sites with the original strain of the 2009 pan-
demic, suggesting that the original strain had an avian
origin. This circulation and mutation of strains in
wild avian species can play a significant role in fu-
ture pandemics.[35–37] Another study displayed that
the original strain of the 2009 pandemic was still cir-
culating in Russia. Randomized trials of healthy and
influenza-infected people showed that a small num-
ber of neuraminidase antibodies were present even in
the healthy individuals, which supports the hypothe-
sis of circulation of strains in the general population.
It was also observed in swine that antibody responses
were extremely different in different individuals of the
species.[38–41] Climate also had a very crucial role in
driving seasonal influenza, as described. The anal-
ysis of different Influenza serotypes affecting several
regions of Australia revealed that the seasonal drives
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Figure 2. Viral load, antiviral therapy, and resistance detection during hospitalization of a patient infected with pandemic influenza A (H1N1)
virus. [Colored squares indicate the absence of resistance mutations (Yellow, Red and Blue), White squares indicate virus-negative samples.
Triangles indicate samples from which no neuraminidase sequence could be obtained. The dashed red line indicates the lower limit of detection
of influenza A semi-quantitative RT-PCR (Real-Time Polymerase Chain Reaction) assay. The duration of oseltamivir monotherapy and zanamivir
monotherapy is indicated by light-gray and dark-gray shading, respectively, and the duration of triple therapy.] [58]
of the virus are most active in subtropical areas. Al-
though the pattern of all inter-seasonal transmissions
is far more complex to comprehend using simple tech-
niques, it is believed that climate is also a major factor
in the drive of seasonal infections.[42–44]
Epidemiological techniques on a molecular level were
used in Europe to quantify the different strains of the
virus that were in circulation after the pandemic of
2009. All the strains within four years after the pan-
demic were analyzed. It was revealed that most of the
strains diverged from the original strain and made the
vaccination process more challenging. The reason be-
hind this is that some of the lineages of the strains were
unresponsive to vaccines and antivirals that were de-
veloped for the virus.[45–47]
Advancement of Modern Antivirals
One of the main potent actions of an antiviral drug
is the inhibition of strain-specific binding receptors.
The blocking of these receptor sites disrupts the infec-
tion cycle and ultimately stops the spread of the virus
within its host. One of these compounds that have
strain-specific activity against the virus is iminosugars
such as NN-DNJ (N-Nonyldeoxynojirimycin) and NB-
DNJ (N-Butyldeoxynojirimycin). Both of these have
shown a high strain-specific potency when their activ-
ity was observed by experimenting on a large number
of Influenza A viruses. NN-DNJ is an α-glucosidase
inhibitor that acts on influenza viruses by disrupting
the main glycan processing between Neuraminidase
and Hemagglutinin. Hemagglutinin is an essential
factor for the proper inhibition of the cycle.[48] Com-
mon antiviral treatment options include oseltamivir
and zanamivir. Both of these antiviral drugs are neu-
raminidase inhibitors and are highly effective against
H1N1 related infections.[49–50]
Recent studies have shown that most of the modern
strains have developed a significant amount of resis-
tance to both of these drugs. Other drugs like ri-
mantadine and amantadine (adamantanes) have also
been developed but these drugs come with their side-
effects like embryonic toxicity and teratogenic abnor-
malities in the developing fetus during the gestation
period.[51–53] Adamantanes are only used in those
cases where Neuraminidase inhibitors based drugs
fail to show any viable potency against the infection.
Sometimes, the combination of adamantanes and Neu-
raminidase inhibitors is more efficient due to their
synergistic effects as displayed by various mice-based
models.[54–56] Early cases of oseltamivir resistance
were reported back in 2017 (Figure 2) in Myanmar
when H1N1 infected patients in a local com-munity
outbreak were analyzed.[57]
Vaccine Mediated Therapies
The most recent development in the field of vaccines is
the use of the AS03 (Adjuvant System 03) type adjuvant
system that exploits α-tocopherol oil and water-based
emulsion of a very precise ratio. A study based on
randomized and controlled trials in adults has shown
that by utilizing the AS03 type adjuvant systems of
vaccine administration, the negative effects of conven-
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Figure 3. Adjusted estimates of influenza vaccine effectiveness [2016–17], overall and stratified according to age, virus subtype or lineage, and
vaccine type.[75]
tional vaccination procedures can be significantly re-
duced with a relatively higher persistence rate. This
produces both humoral and cell-mediated immune re-
sponses following the induction of CD8 T-cells (Cluster
of Differentiation 8 Thymus cells).[59-60]
Furthermore, antigen selection and cross-protection
process can be improved by using a nomenclature sys-
tem that is easy to comprehend and is based on the
phylogeny of Hemagglutinin based lineages. A total
of 7,070 H1 sequences were used for the development
of the nomenclature annotation tool that yields 99% ac-
curate results most of the time.[61–62] Modern techno-
logical development has made it possible to study the
interactions of vaccines by using computational sim-
ulation analysis and constructing various Mathemat-
ical models. These computationally optimized vac-
cines have shown their activity over a broad range of
Influenza A viruses isolated from human and swine
subjects.[63–67] Recently developed COBRA (Compu-
tationally Optimized Broadly Reactive Antigen) vac-
cines with HA (Influenza Hemagglutinin) antigen are
optimized in such a way that most zoonotic infections
were prevented in farmworkers as shown in a study by
Morris and colleagues.[68–70] miRNA (micro Ribonu-
cleic Acid) alteration technologies are a kind of new ap-
proach to deal with the virus with a unique strategy. It
has been observed that especially developed miRNA
such as miR-let-7b-MRE enhances the biosafety for de-
veloping more operative and stable vaccines by de-
creasing the replication and virulence of the virus.[71–
74]
Neutralization can be achieved by using monoclonal
antibodies that have performed well in experimental
assays to study antigen-antibody interactions (Figure
3). Such an example is murine-based high-affinity
MA2077 neutralizing monoclonal antibody that in-
hibits the 2009 strain of Influenza A in a specifically
developed experimental assay. The specificity of this
monoclonal antibody lies with the ‘Sa’ site in an in vitro
medium.[76] Chicken eggs are generally used as a ba-
sic medium to reproduce viruses and then to produce
vaccines along with, but a new type of approach uti-
lizes attenuated metabolically active E. coli to produce
an enormous amount of antibodies before primary im-
munization in a short span of about three weeks. This
method can be used as an efficient way to study vac-
cines without applying any rigorous purification pro-
cedures for deriving antigen. On the other hand, this
method is much faster than other lengthy conventional
methods because it only employs E. Coli based har-
vested Hemagglutinin. This Hemagglutinin produces
a detectable amount of antibodies when observed in
MDCK (Madin-Darby Canine Kidney) cells. Further-
more, this immunization technique doesn’t require any
exogenous adjuvant as a booster dose.[77–80]
Modern Research and Progress
There is a reinforcement problem that exists in the cases
of co-infection such as Influenza A Virus in a combi-
nation with the hRSV (Human Respiratory Syncytial
Virus). It has been observed that during normal sea-
sonal peaks of both viruses, the ferrets with co-infection
show an increase in the levels of pro-inflammatory cy-
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tokines. This happened when the inoculum dose was
increased more than normal with the same ratio of
hRSV. This phenomenon is mostly termed as viral in-
terference that increases the challenges while dealing
with a subject of co-infection. Immune mediators with
other chemokines were also released upon increas-
ing the dosage that poses the possibility of antigen-
independent mechanisms that drive the interference
process.[81] Later, it was found that autophagy is a pro-
cess that defines the interaction of dendritic cells with
several strains of influenza viruses as observed in mice
models.[82] Although the seasonal viral spread can be
explained with a reverse zoonosis strategy that pro-
motes the development of new lineages, viral interfer-
ence is not perfectly understood yet.[83–84]
A recent study in hosts other than birds and swine
showed that host jumping of several strains of In-
fluenza A is a major threat in control of any future pan-
demics. Canines and Equines usually have a very sta-
ble lineage of Influenza A viruses. The samples that
were taken from different southern China (2013–15),
upon sequencing have shown that the virus is slowly
mutating when the interaction of these species with
major reservoirs of Influenza A virus occurs. It means
that host jumping can contribute to the development of
new lineages in minor hosts as well.[85–87] Similarly,
experimental studies also support the transmission of
the virus from different avian species into mammals.
The virus adapts to the host body by exploiting specific
HA-receptors.[88]
Modern methods of characterization mostly depend
upon the genetics of the agent that is being exam-
ined. One of the profound examples of using ge-
netic methods was the characterization of a strain of
Influenza A present in native pigs of Ontario, CA.
The 99% triple re-assortment based identity match of
subtypes like H3N2 with the original strain of 2009
confirmed their origin from pigs. Furthermore, the
Ontario based strain posed significant resistance to
adamantanes but was immensely responsive to Neu-
raminidase inhibitors based drugs.[89–92] Other meth-
ods still work effectively as shown in an experiment
(mice and ferret models) of combined factor vaccines
(both Hemagglutinin as well as Neuraminidase) that
were utilized to produce a significant amount of im-
mune responses in research subjects.[93–94] Song and
colleagues conducted a pathogenic study on the corre-
sponding lineages of Chinese swine and humans (NS,
PA, PB2, NP, M, NA, and PB1) by using several tech-
niques and methods to differentiate strains in the lab-
oratory. The study concluded that the viral strain in
the Chinese swine sample was homologous with the
strain that was previously circulating in North Amer-
ican regions. On the other hand, there were several
variations in the pathogenicity when compared to other
mammal-infecting strains. Mice models were used for
histopathological examinations that showed that the
viruses (AV1522, AV1523) progress over time due to
the re-assortment in Chinese swine. It ultimately af-
fects the respiratory as well as the nervous system of
the infected individuals.[95–98] Furthermore, the con-
tinual resistance of the virus against modern antivi-
rals drugs and vaccines makes it more challenging for
researchers to develop new treatment strategies. The
new anti-influenza agents that are still evolving and
are in rigorous development include RNA (Ribonucleic
Acid) inhibitors, RdRp (RNA-dependent RNA poly-
merase) inhibitors, V-ATPase (Vacuolar-type Adeno-
sine Tri-Phosphatase) inhibitors as well as some species
of modified antioxidants.[99–103]
Conclusion
Although the present-day scenario is far more different
from the circumstances during the pandemic of 2009,
we should always be ready to deal with the unforeseen
circumstances. The complications related to the infec-
tion caused by the different strains of the virus are now
under control due to the rapidly evolved technology
that enabled us to develop more effective treatments
and advanced therapeutic methodologies. These de-
velopments helped people on a global scale in recent
decades.[104] If we discover a new strain of the virus
with a pandemic causing potential, the management
strategies would be less complex because of our far
more developed global management system. Overall,
we are optimistic that we shall find a cure for this infec-
tion as we always have.
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